Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00046683
Status:
COMPLETED
Last Update Posted:
2016-07-28
First Post:
2002-10-01
Brief Title:
EfficacySafety of Frontline Alemtuzumab Campath MabCampath vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Organization Data
Organization:
Sanofi
Class:
INDUSTRY
Study ID:
CAM307
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Genzyme a Sanofi Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None